2150 – 885 West Georgia Street
Member Sector: Biopharmaceuticals
ProNAi Therapeutics is a private company dedicated to developing and commercializing a new class of therapies based on its proprietary DNAi platform for patients with cancer and hematological diseases. ProNAi’s lead DNAi drug PNT2258 is specifically designed to treat cancers that overexpress BCL2. To date, 35 patients have been treated with PNT2258 in a Phase I and a pilot Phase II trial, with compelling efficacy and safety results reported. For more information, please visit www.pronai.com.